Please check your internet connection and try again.
# Tab%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525%20voihep
## Overview
Tab%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525%20voihep is a combination antiviral medication containing sofosbuvir and velpatasvir, used for the treatment of chronic hepatitis C virus (HCV) infection.
## Primary Indications
Chronic Hepatitis C Virus (HCV) genotypes 1, 2, 3, 4, 5, and 6 infection.
## Adult Dosing
**1 tablet (sofosbuvir 400 mg/velpatasvir 100 mg) orally once daily.**
Treatment duration is typically 12 weeks. For patients with decompensated cirrhosis or those who have previously failed treatment, a 12-week course may be extended to 24 weeks, often in combination with ribavirin.
## Pediatric Dosing
Dosing for pediatric patients is not established for this specific combination product. Consult relevant pediatric guidelines or specific pediatric formulations if available.
## Dose Adjustments
No dose adjustment is necessary for mild to moderate renal impairment (eGFR $\ge$ 30 mL/min/1.73 m$^2$).
**Severe renal impairment (eGFR < 30 mL/min/1.73 m$^2$) and end-stage renal disease:** Use with caution. Data are limited, and no dose adjustment recommendations are available.
**Hepatic Impairment:** No dose adjustment needed for mild to moderate hepatic impairment (Child-Pugh A and B). **Severe hepatic impairment (Child-Pugh C):** Use with caution; safety and efficacy have not been fully established.
## Contraindications
* Hypersensitivity to the active substances or any excipients.
* Use with potent P-glycoprotein (P-gp) inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort) due to potential significant reduction in plasma concentrations of sofosbuvir and velpatasvir.
## Adverse Effects
Common adverse effects include headache, fatigue, nausea, insomnia, and anemia (especially if used with ribavirin).
## Key Drug Interactions
* **Potent P-gp inducers:** Avoid concomitant use (see Contraindications).
* **Antacids, H2-receptor antagonists, and proton pump inhibitors (PPIs):** May decrease velpatasvir exposure. Separate administration by at least 4 hours for antacids, 12 hours for H2-receptor antagonists, and 12 hours before or 4 hours after PPIs.
* **Efavirenz, modafinil:** May decrease plasma concentrations of sofosbuvir and velpatasvir.
* **Certain antiretrovirals (e.g., ritonavir-boosted regimens):** May increase sofosbuvir concentrations.
## Monitoring
* Baseline HCV genotype and resistance testing may be considered.
* Monitor for adverse effects.
* Assess for sustained virologic response (SVR) 12 weeks after completion of therapy.
## Clinical Pearls
* This regimen is effective across all major HCV genotypes and can be used in treatment-naïve and treatment-experienced patients.
* Consider baseline liver function tests and renal function.
* Ensure adequate contraception is used by both male and female patients during treatment and for at least 6 months after completion due to potential teratogenicity of ribavirin if used concurrently.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant guidelines for complete and up-to-date guidance before making any treatment decisions.*
